You and abeta are moving right on target. Now consider what you wrote about macrophages and T-cells having quicker and longer access to targets in m+. Not all T-cells or macrophages are actually beneficial when brought into the fight. They must receive the proper signalling as a group to prevent shutting down the immune response. I don't want to delve too deeply into this for obvious reasons but NWBO has mostly figured out how to properly program DCs to provide the right signalling so that T-helper and macrophage cells don't end up interfering with a proper immune response against the cancer. They also found out that this signalling must be properly maintained during the course of tumor destruction or the tumor will be given a chance to reemerge. They learned quite a bit from this trial and Direct Phase 1 and some patients will be better served by obtaining L much earlier than they did in this trial. By the way, EGFR is an easier target to reach so when it is depleted in some types of GBM the benefit from targeting this is limited and a resulting shorter OS occurs in these patients compared to meth+ with greater expression of EGFR. Best wishes.
News 
Market Data 
Discover 
